AbbVie (ABBV.US)'s Upadacitinib extended-release tablets for new indications are expected to be included in priority review.

09:23 13/03/2026

AbbVie (ABBV.US) has proposed a new indication for the extended-release tablets of Upadacitinib to be included in priority review, intended for the treatment of non-segmental vitiligo in adults and adolescents aged 12 and older.

On March 12th, according to the CDE official website, AbbVie's new indication for Upadacitinib extended-release tablets is proposed for priority review, intended for the treatment of non-segmental vitiligo in adults and adolescents aged 12 and above. Upadacitinib is a selective JAK inhibitor, and also a key product under AbbVie, with global sales expected to reach $8.304 billion by 2025 (+39.07%). Source: CDE official website The application for priority review this time is targeting a new indication: non-segmental vitiligo in adults and adolescents aged 12 and above. Regarding this indication, just this February, AbbVie announced that they have submitted a new indication application for Upadacitinib for the treatment of non-segmental vitiligo in adults and adolescents to the US FDA and the European EMA.

Industrial: How do high oil prices affect US inflation and Federal Reserve actions?

EB SECURITIES: AI inflation is giving birth to a new cycle, and the price increase of optical fiber and copper-clad laminate is driving the growth of industry companies.

Microsoft Corporation (MSFT.US) Azure takes the lead and becomes the first global cloud service provider to begin validating the NVIDIA Corporation Vera Rubin NVL72 system.

Industrial: How do high oil prices affect US inflation and Federal Reserve actions?

EB SECURITIES: AI inflation is giving birth to a new cycle, and the price increase of optical fiber and copper-clad laminate is driving the growth of industry companies.

Microsoft Corporation (MSFT.US) Azure takes the lead and becomes the first global cloud service provider to begin validating the NVIDIA Corporation Vera Rubin NVL72 system.